←Back to Expert Scholars
Translational Medicine / 转化医学HER2 Therapy Clinical Development
Kimberly Blackwell
MD
🏢Duke University / Eli Lilly and Company🌐USA
Former Professor of Medicine
65
h-index
0
Key Papers
0
Key Contributions
👥Biography 个人简介
Kimberly Blackwell led pivotal trials that established trastuzumab emtansine in HER2-positive metastatic breast cancer. Her translational career has spanned academia and pharmaceutical clinical development. She continues to guide drug development for breast cancer.
Share:
🧪Research Fields 研究领域
HER2 breast cancer
trastuzumab
T-DM1
clinical development
pertuzumab
🎓Key Contributions 主要贡献
Representative Works 代表性著作
📄Data Sources 数据来源
Last updated: 2026-04-01 | All information from publicly available academic sources
Related Experts 相关专家
Antoni Ribas
UCLA Jonsson Comprehensive Cancer Center
Melanoma ImmunotherapyCheckpoint Inhibitors
Drew M. Pardoll
Johns Hopkins University
Cancer ImmunologyPD-1/PD-L1 Pathway
Padmanee Sharma
MD Anderson Cancer Center
Bladder Cancer ImmunotherapyImmune Profiling
Naiyer A. Rizvi
Columbia University Irving Medical Center
Lung Cancer ImmunotherapyTumor Mutational Burden
关注 Kimberly Blackwell 的研究动态
Follow Kimberly Blackwell's research updates
留下邮箱，当我们发布与 Kimberly Blackwell（Duke University / Eli Lilly and Company）相关的新研究或访谈时，我们会通知你。
Explore More Experts
Discover the researchers shaping the future of cancer treatment